Other News To Note
Wednesday, November 16, 2011
Avraham Pharmaceuticals Ltd., of Jerusalem, raised $3 million from Yissum Research Development Co. Ltd., the technology transfer arm of the Hebrew University of Jerusalem, and other investors. The funding will be used for an ongoing Phase II trial of ladostigil in Alzheimer's disease and a planned study of the drug in mild cognitive impairment. Ladostigil is a cholinesterase and brain-selective monoamine oxidase inhibitor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.